Strategies for Success: Using Long-Acting Injectable Medications-Presentation Q&A

Video Transcription

Video Summary

In this video transcript, the speaker answers questions regarding the use of long-acting injectables (LAI) for patients with psychosis. The first question asks if every patient should be started on LAIs based on the data presented. The speaker believes that in a society that is less avoidant and stigmatizing, LAIs would be first-line treatment. The second question asks about characteristics of patients that make them good candidates for LAIs, to which the speaker responds that there is no specific sub-population that benefits more from LAIs. The video also addresses the duration of oral medication before transitioning to LAIs and managing side effects such as over-sedation and confusion. The speaker recommends involving primary care physicians in initiating and delivering LAIs and discusses considerations for transitioning patients from inpatient to community care. There is also a discussion about managing hyperprolactinemia in patients who respond well to Risperidone or Paliperidone. The video concludes with a mention of a poster presented at ACNP about transitioning patients to LAIs while they are institutionalized. Overall, the video provides insights and recommendations on the use of LAIs in the treatment of psychosis.

Keywords

long-acting injectables

psychosis treatment

patient characteristics

side effects management

community care transition